Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. Eugen-Olsen J, et al. Among authors: lyngbaek s. J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28. J Intern Med. 2010. PMID: 20561148 Free article.
Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?
Olsen MH, Sehestedt T, Lyngbaek S, Hansen TW, Rasmussen S, Wachtell K, Torp-Pedersen C, Hildebrandt PR, Ibsen H. Olsen MH, et al. Among authors: lyngbaek s. Curr Vasc Pharmacol. 2010 Jan;8(1):134-9. doi: 10.2174/157016110790226633. Curr Vasc Pharmacol. 2010. PMID: 19485906
Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR. Lyngbæk S, et al. Am J Cardiol. 2012 Dec 15;110(12):1756-63. doi: 10.1016/j.amjcard.2012.08.008. Epub 2012 Sep 13. Am J Cardiol. 2012. PMID: 22981263
Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group. Lyngbæk S, et al. Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30. Eur J Prev Cardiol. 2014. PMID: 23723326 Clinical Trial.
26 results